View
225
Download
0
Category
Preview:
Citation preview
Epidemiological Situation of Hepatitis C in Turkey
Selda ErensoyEge University, Faculty of Medicine
Microbiology and Clinical Microbiologyİzmir
selda.erensoy@ege.edu.tr
Anti-HCV SeroprevalenceBlood donorsGeneral population – age groupsHemodialysis patientsHealth care workersDifferent patient groupsRisk groupsRisk factorsSexual partners and offsprings of chronic hepatitis C patients
0.5
0.5-0.7
0-0.3
1
0.5-3.21.3
0.3-0.7
1.20.3
0.3-1.6
Anti-HCV Seropositivity in blood donors (%)1995 – 1999 (~ 0.6%) / 2000-2007 (~ 0.54%)
0.6-2.11.4
0.7
1.1
0.2-0.7
0.3-1.5
0. 7
0.3-0.5 0.2
0.14
0.2 0.1
0.2-0.5
0.6
0.3-0.8
0.5
1.5
1
0.5-10.6
3.4
0. 70,07
0,810.37
0.68
1.1
Routine screening of anti-HCV has been started in all blood centers in Turkey in 1997.
Trends in HCV among blood donors over 8 years; 1996-2004Gurol E, 2006
0.27% increase 0.13% decreasePrimary screening: 0.60%Repeatable reactive: 0.58%Confirmation: 0.41%Indeterminate: 0.12%
Primary screening: 0.55%Confirmation: 0.35%
1996 - 2004; confirmed: 0.38%
0.13
0.48
0.29
0.28 0.81
0.44
0.37
0.46
0.47 0.33
0.49
0.670.52
0.34
0.870.55
0.19
0.95
0.25
0.33
0.26
Trends in HCV among blood donors over 8 years; 1996-2004Gurol E, 2006
0.4
1.7
0.17
Anti-HCV Seropositivity in General Population (%)1995 – 2009
(age: 0 – 99 years)
0.461.2
1
1.91.1-2.8
2.2
Children:Konya; n:460 (2 mnt -17yrs) 0,21% in 1999Diyarbakır; n:528 (5-16 yrs) 0,56% in 1999İstanbul; n:198 (11-14yrs) 0% in 2003
2.1
2.1
anti-HCV seropositivity in İstanbul 1999
0,00
0,50
1,00
1,50
2,00
total 0-4 5-9
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-85
age (years)
%
n:119062 80
0,17
1,61,25
72 58 46 91 349128 98 46 39 32
89
Pahsa A; 1999
anti-HCV seropositivity in Ankara 1999
0,00
0,50
1,00
1,50
2,00
2,50
total 0-18 19-38 39-58 59-78 79-99
age (years)
%
Yousefi AR, 1999
n:3035 n:52 n:603 n:1139 n:1202 n:39
1,7
00,8
2,1 2
0
anti-HCV seroprevalence in Ankara 2003
0,000,200,400,600,801,001,201,401,60
1-5 6-10 11-15
16-20
21-25
26-30
31-35
36-40
41-45
46-50
51-55
56-60
age: years
%
Kurt H; 2003
anti-HCV seroprepalence in Kırıkkale in2003
0
1
2
3
4
5
6
0-19 20-39 40-59 60-
age
%
Seri 1Seri 2
Kaygusuz S, 2003
Female
Male
N (47) (284) (927) (689) (312) (293) (103) (59)
1,40,4 0,6
1,3
0,31
4,9
1,7
Anti-HCV seroprevalence in Tokat and Konya
012345678
0-11 18-29 30-39 40-49 50-59 60-69 70-79 >80 total
age: years
%
Seri 1Seri 2TokatVan
n:1095
n:40000,6 1
2,3 2,3
4 3,9
1,22,1
0,8
4,23,4
7,1
Tokat; Black Sea region of TurkeyVan; Eastern Turkey
Van
There is no significant difference between rural versus urban Yıldırım B, 2009Bozkurt H, 2008
1,2
14,4
18,6-66,6
32,7-62,7
82,8
28,5-32,7
1760,9
81,6
30,7-53,2
20,6-49,3 32,4-73,643,2 54,6
38,8
40,0-79,1
56,9-65,0
20,0
Anti-HCV Seropositivity in hemodialysis patients1991 – 1999 (41,5%)2000-2006 (27,4%)
5,9-43,6
43,581,4
52,3
45-52
49,6
Multi-center study (2005): 28%
12-20
1941
4,7
Multi-center (1995): 49,5%
1,3
0,5-1,7
0
0
0-0,70
1,1
0,2-0,9
0-1,6
0,4
2,9
Anti-HCV Seropositivity in Health Care Workers1992 – 1999 (~ 0,7%)2000-2006 (~ 0,4%)
n: 26 (1994; Bursa; hemodialysis; 0) - 54 (2005; Bursa; anaesthesiology; 0)n: 577 (1994; İstanbul; 0,2%) n: 703 (2006; Manisa; 0.15) n: 95 (2000; Malatya;hemodialysis; 2,1%)
0-1,1
0,5
0
0,96
0
0,15- 0,22,1
0
5,7
4
5,7-3,3
3,9
2,3-3,2
10,3
12
Anti-HCV Seropositivity in Prostitutes(%) 1992 – 2000 (~ 4,55%)
Sivas 1995: 12%İzmir 1993: 3,2 – 1998: 2,3%)
Diyarbakır 1992: 5,7% - 2000: 3,3%Malatya 1992: 10,3%
Patient groups Province number Anti-HCV + (%)
Hematologic dis. / +multl. transfusion
AdanaAnkaraMalatyaSamsunHatayMulticenter
40 103583399999
12,5202,830,14,512,6
children Hematol/oncolog.dis (6mt-18yrs)Acute lymph. Leukemia (2-10)Solid tm (1-16yrs)
DiyarbakırAnkaraİstanbul
7216050*transfusions
23,61,92 (at diagnosis)14 (end)
Renal Tx AdanaAnkaraİstanbul
417435
12,552,748,5
Renal Tx (PTDM-)Post Tx diabetes mell.
İstanbul 4343
3772
Patient groups Province number Anti-HCV + (%)
Renal tx AdanaAnkaraİstanbul
417435
12,552,748,5
Psychiatric Pat. ElazığManisa
158180
2,531,7
IV drug users İstanbul 82107
54,844,9
Patient groups Province number Anti-HCV + (%)
Non-hodg. Lymph. AnkaraİstanbulAnkaraErzurumAdana
3130-8433470223-228
22,513-7,11,81,48,1-11,1
Lymphoproliferative disorders
Gaziantep 334 2,6
Lichen planus AnkaraGaziantepDiyarbakırAnkara
417312854
4,86,86,212,9
Behçet’s Disease İzmirAnkaraİstanbulKırıkkale
137355074
0,8002,7
Hepatic disease Province number Anti-HCV + (%)
Chronic liver disease
Ankara (1991)İstanbul (1997)İzmir (1996)
101526107
163518
HCC Ankara (1987)Diyarbakır (1992-93)İzmir (1996)Multicenter (1994-2007)
35-3131221
1517/12,52921,3
Cryptogenic hepatitis
Ankara (1992)İstanbul (1991)Adana (1991)
786429
26,95272,4
Chronic B hepatitis Adana (1991)İstanbul (1991)
129 132
1812
Alcoholic cirh. İstanbul (1991) 20 20
1,4%
2 -2,7%2%
0,5%(children)
İstanbul (n:720) 1998 İzmir (n:398-518) 1998 /2000Diyarbakır (n:148) 1998
Adana (n:388 children) 1998
HCV etiology in Acute viral hepatitis
3%
Konya 1990-2004 (retrospective)
Anti-HCV (+) %
Akçam FZ, 2009Isparta
Anti-HCV (+) %
Anti-HCV (+) % Anti-HCV
%
Risk Factors for the transmission of HCV infection in Turkish population (%)
Surgical operation 98,1- 68,9- 64,9Transfusion 39,7- 21,2- 24,1Dental procedure 27,5- 77,5- 73,8Abortion 21,2Hemodialysis 10IV drug abuse 3,1- 1,3- 0Long-hospitalization 3,1- 8,4Multi-partner sex 1,5- 12,6- 0,5Other (tattooing, acupuncture, sharing razors etc.)
8,1- 8,5- 3,7/6,8
Karaca Ç, 2006 (1996-2002; İstanbul-320pts)
Yıldırım B, 2005 (1997-2001; İstanbul-151)Aykın, 2008 (2002-2006; Afyon-191)
Anti-HCV seroprevalence in sexual partners and children of chronic Hepatitis C
Province Index case (n)
n HCV(+)%
Sexual partners
Afyon (2003)1
İstanbul (2005)3
İstanbul (2004)4
174600109
174600109
3,425,5
Children Afyon (2003)1
İstanbul (2003)2
191107
230222
2,171,35
1.Aykın N, 2003; 2.Tahan V, 2003; 3.Tahan V, 2005; 4.Yenice N
Conclusions -1Anti-HCV has been screened in all blood centers in Turkey since 1997.Seroprevalence of HCV among blood donors: 0,2-1,1% (0,5%).Epidemiological studies differ in sample size and sampling methodologies.HCV seroprevalence in general population: 0,17-2,8.
* Higher at the ages over 35.Lower in western part of Turkey.
HCV seroprevalence among hemodialysis patients:
Significant decrease from 1996 to 2006(41,5% 27,4%)
Seroprevalence is low among health care workers in Turkey; decrease (0,7% to 0,4%)Comparative studies regarding different groups (doctors versus nurses, other employee) are meaningful.
Conclusions - 2
Multiple transfusion has an impact on anti-HCV seroprevalence (especially before 2000 and in older patients): 4,5% - 30%Anti-HCV seroprevalence is high among IV drug users (45-55%).Seroprevalence is high among non-Hogkin lymphoma (1,4% - 22,5%).High among patients with liver disease (chronic liver dis., hepatocellular carcinoma, cryptogenic cirrhosis): 11-72%.
Conclusions - 3
No significant difference in anti-HCV seroprevalence between males and females.Most of the contributing risk factors for the transmission of HCV are;History of blood transfusionHistory of surgeryHistory of hospitalization (invasive procedures)Most of the anti-HCV positive patients are HCV RNA positive (>50%).
Conclusions - 4
References• ……….. Mıstık R and Balık İ, 2001and 2007 (Turkish Viral Hepatitis Prevention Society) ………• Gürol E et al., 2006.• Yıldırım B et al., 2005, 2009.• Bozkurt H et al., 2008.• Erden S et al., 2003.• Akçam FZ et al., 2009.• Özcan E, Alpaslan G, 2001• Coşkun Ö et al., 2006.• Koçak N et al., 2004.• Öztürk C, Delialioğlu N, 2001.• Afşar i et al., 2009.• Ağuş N et al., 2008.• Kaya S et al., 2005.• Sakarya S et al., 2004.• Dursun D et al., 2004.• Kocamanoğlu IS et al., 2003.• Işıkdoğan A et al., 2003.• Bozdayı G et al., 2002. ………….
• Sertöz R et al., 2003. • Afşar B et al., 2009.• Yakaryılmaz F et al., 2006.• Kanbay M et al., 2006.• Sit D et al., 2007.• Selçuk H et al., 2006.• Olut A et al., 2005.• Ocak S et al., 2006.• Aykin N et al., 2008.• Karaca Ç et al., 2006.• Tahan V et al., 2005.• Yenice N et al., 2003, 2004.• Mırsal H et al., 2003.• Alacacioğlu A et al., 2008.• Tavil B et al., 2007.• Kaya H et al., 2002.• Arslan Ü et al., 2009.• Okan V et al., 2008.• Mutlu B et al., 2004.• Akbayır N et al., 2004. ………...
• Karavelioğlu D et al., 2004.• Kırtak N et al., 2000.• Harman M et al., 2004.• Erkek E et al., 2001.• Aksu K et al., 1999.• Dikici B et al., 2002.• İlter N et al., 2000,• Kebudi R et al., 2000• Atabek ME et al., 2000.• Paydaş S et al., 2003, 2005.• Yamaç K et al., 2000.• Yılmazlar A et al., 2005.• Özgün MT et al., 2009.• Demirtürk N et al., 2006.• Candan F et al., 2002.• Tekay F, 2006.• Öner M et al., 2007.• Sönmez M et al., 2007.• Gündüz T et al., 2005.• Harmankaya O et al., 2002.• Aydın F et al., 2002………………
• Özsoy MF et al., 2003.• Ayrancı U, Koşgeroğlu, 2004.• Özer ZC et al., 2008.• Cesur S et al., 2003.• Kavak A et al., 2002.• Yıldız A et al., 2002.• Kadiroğlu AK et al., 2005.• Altındiş M et al., 2006.• Kandemir M et al., 2006.• Utkan G et al., 2006.• Özdemir Ö et al., 2003.• Banak S et al., 2002.• Kanlıöz M et al., 2002.• Kargı E et al., 2003.• Tekerekoğlu M et al., 2001.• Yılmaz ME et al., 2000.• Oldaçay M et al., 2004.• Maral I et al., 2009.• Alim A et al., 2009.• Gülcan A et al., 2008.• Arıcan A et al., 2000• Kandemir B, et al., 2005 ………………
THANK YOU FOR
YOUR ATTENTION
Recommended